Carlyle acquires Corrohealth (2024)

Deal facts

Buyer: Carlyle
Target: Corrohealth
Deal value: Not disclosed
Announced: 3 November 2024
Status: In review
Sector: Other
Country: Not stated
Consideration: Not stated

Sources

EU_DG_COMP

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

2 Dec 2024CMA invitation to comment
PATIENT SQUARE / CARLYLE / CORROHEALTH
PATIENT SQUARE / CARLYLE / CORROHEALTH
EU DG COMP

OpinionExit Mode editorial

We see a clear signal in the announcement that Carlyle is acquiring Corrohealth, a move that places private equity capital squarely within the 'Other' sector classification. The deal was announced on 3 November 2024 and currently sits in review. This status is not a mere formality but a critical phase where the commercial logic of the transaction faces its first real test. For the SME founder watching from the sidelines, this moment highlights how even established platforms require rigorous scrutiny before capital changes hands. The absence of a disclosed value or currency figure is typical for this stage, yet it underscores that the primary hurdle right now is not price but permission.

The 'in_review' status almost certainly points to regulatory clearance requirements under UK or EU competition frameworks. When a major global buyer like Carlyle enters a niche sector, authorities will examine whether the transaction creates a monopoly or stifles competition. This is not a theoretical risk but a concrete mechanic that can delay completion or force structural remedies. Founders must understand that change-of-control covenants in their existing contracts could be triggered by this review, potentially affecting day-to-day operations or access to credit lines. The deal mechanics here are dictated by the regulator, not just the negotiation table. We observe that the sector label of 'Other' often invites closer inspection because it lacks the clear benchmarks of more defined industries, making the regulatory path less predictable.

The path forward for Corrohealth depends entirely on navigating these clearance procedures without losing momentum. We think the most prudent course of action is to prepare a robust defence of the competitive landscape. This means gathering evidence that shows how the business operates independently and why the acquisition will not harm market dynamics. The review period is a time for active management, not passive waiting. Founders should treat this phase as a continuation of the due diligence process, ensuring all commercial data is ready for regulator scrutiny.

Your immediate task this week is to conduct a full audit of your change-of-control clauses and identify any third-party contracts that require consent upon a sale. Do not wait for the regulator to ask; proactively list every agreement that could be jeopardised by the review status and prepare the necessary notification letters.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Other deals More 2024 deals More pe acquisition deals More from Carlyle All M&A deals

Similar deals

Other Other M&A activity tracked by Exit Mode.

15 June 2026Firm intentionOther

APOLLO FUNDS to acquire FORVIA AUTOMOTIVE INTERIORS BUSINESS

Apollo Funds has agreed to acquire the Forvia Automotive Interiors Business in a private equity acquisition. The transaction was announced on 15 June 2026 under firm int…

Buyer: APOLLO FUNDS
Target: FORVIA AUTOMOTIVE INTERIORS BUSINESS
Deal value: Not disclosed
Deal type: pe acquisition

Read deal Other deals pe acquisition deals Announced deals

25 March 2026Firm intentionOther

Permira / Warburg Pincus to acquire Clearwater Analytics

PERMIRA, Warburg Pincus and Clearwater Analytics have agreed to acquire a target company in a private equity acquisition announced on 25 March 2026. The specific name of…

Buyer: Permira / Warburg Pincus
Target: Clearwater Analytics
Deal value: Not disclosed
Deal type: pe acquisition

Read deal Other deals pe acquisition deals Announced deals

12 November 2025In reviewOther

LONE STAR FUNDS to acquire HILLENBRAND

LONE STAR FUNDS and HILLENBRAND entered the Exit Mode archive.

Buyer: LONE STAR FUNDS
Target: HILLENBRAND
Deal value: Not disclosed
Deal type: pe acquisition

Read deal Other deals pe acquisition deals In review deals

6 April 2025In reviewOther

Carlyle / SK Capital Partners to acquire bluebird bio

CARLYLE, SK Capital Partners and Bluebird have agreed to acquire a private company in a private equity acquisition announced on 6 April 2025. The transaction involves a…

Buyer: Carlyle / SK Capital Partners
Target: bluebird bio
Deal value: Not disclosed
Deal type: pe acquisition

Read deal Other deals pe acquisition deals In review deals

20 October 2024In reviewOther

CARLYLE to acquire VANTIVE

CARLYLE and VANTIVE entered the Exit Mode archive.

Buyer: CARLYLE
Target: VANTIVE
Deal value: Not disclosed
Deal type: pe acquisition

Read deal Other deals pe acquisition deals In review deals

Buyer history

Carlyle

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

Carlyle to acquire Corrohealth

Deal facts

Explore the Toolkit

Deal timeline

Browse adjacent archives

Similar deals

APOLLO FUNDS to acquire FORVIA AUTOMOTIVE INTERIORS BUSINESS

Permira / Warburg Pincus to acquire Clearwater Analytics

LONE STAR FUNDS to acquire HILLENBRAND

Carlyle / SK Capital Partners to acquire bluebird bio

CARLYLE to acquire VANTIVE

Carlyle

How this page is built